Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FOLFIRINOX + carbon ion radiation therapy
- Development stage
- Unknown
- Lead developer
- CNAO Foundation
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This neoadjuvant treatment regimen, evaluated in the PIOPPO Phase II clinical trial, combines the multi-agent chemotherapy protocol FOLFIRINOX with carbon ion radiation therapy (hadrontherapy) for patients with resectable or borderline resectable pancreatic adenocarcinoma. FOLFIRINOX consists of oxaliplatin (a DNA cross-linker), irinotecan (a topoisomerase I inhibitor), leucovorin (a folinic acid derivative that potentiates fluorouracil), and fluorouracil (a thymidylate synthase inhibitor). Carbon ion therapy utilizes high-LET (linear energy transfer) radiation to deliver a precise dose to the tumor (Bragg peak), offering superior relative biological effectiveness compared to conventional photon-based radiotherapy. The goal of this multimodal approach is to increase the rate of R0 surgical resections and improve relapse-free survival in patients with localized pancreatic cancer.
- Other names
- Preoperative FOLFIRINOX and Carbon Ion TherapyHadrontherapy for pancreatic cancerPreoperative chemotherapy-CNAO National Center of Oncological Hadrontherapy-pancreatic adenocarcinoma
02
Targets
DNATOP1 (DNA Topoisomerase I)TS (Thymidylate synthase)
Beyond the preview
Go deeper on FOLFIRINOX + carbon ion radiation therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FOLFIRINOX + carbon ion radiation therapy.